Vivos Therapeutics Shares Drop 4.26% as Proxy Meeting Proposals Set Stage for 2026
Vivos Therapeutics’ Q4 update: stock dip, $4.5M market cap, and 2026 annual meeting proxy details, plus peer comparison and product focus.
3 minutes to read
VIVOS THERAPEUTICS INC
Vivos Therapeutics (VVOS) Slides 4.26% to $0.13, Market Cap $2.8M, Amid Sector‑Wide Softness
VVOS shares fell 4.26% to $0.13, trading below a $0.81 200‑day SMA and outpacing peers, with a $2.8M market cap amid volatility in the sleep‑tech sector.
2 minutes to read
Vivos Therapeutics Gains 4.44% as Strategic SOD Sciences Deal Boosts Sleep‑Disorder Solutions
Vivos Therapeutics’ 4.44% rise fuels a $10.8M trading day as it partners with SOD Sciences, sharing equity, a pseudohypoxia test, and new revenue streams in the sleep‑disordered breathing market.
3 minutes to read